Vitamin d derivative may help keep bones strong after menopause
NCT ID NCT07660536
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This trial investigates whether doxercalciferol, a form of vitamin D, can prevent bone loss in the spine and thigh bone in postmenopausal women with low bone density. Participants take either doxercalciferol or a placebo daily for two years, with bone density measured at the start, 12 months, and 24 months. The goal is to see if this drug can help maintain bone strength and reduce fracture risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- doxercalciferol
- What this could lead to
- If it works, this could point toward a non-hormonal option to slow bone loss and reduce fracture risk in postmenopausal women.
- What could go wrong
- This is a small, early-to-mid-stage trial. The drug may not improve bone density more than placebo, and side effects like elevated calcium levels are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE MINERAL DENSITY OF SPINE AND FEMUR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Creighton University Medical center
Omaha, Nebraska, 68132, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.